Collaborations, Dividends, New Drug Applications, and Technical Updates - Research Reports on Simon, Regions Financial, American Capital, CareFusion and Alexion

NEW YORK, October 21, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Simon Property Group Inc. (NYSE: SPG), The Regions Financial Corporation (NYSE: RF), American Capital Agency Corp. (NASDAQ: AGNC), CareFusion Corporation (NYSE: CFN) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7336-100free.

--
Simon Property Group Inc. Research Reports
On October 3, 2014, Simon Property Group Inc. (Simon) announced the launch of an exclusive SHOES FIRST ™ Shopping Guide, inspired by Marie Claire Creative Director Nina Garcia's famous fashion philosophy that, "Every amazing outfit first starts with a fabulous pair of shoes." According to the Company, The SHOES FIRST Shopping Guide is available to shoppers at four of Simon's premier fashion destinations: Copley Place in Boston, The Forum Shops at Caesars in Las Vegas, Phipps Plaza in Atlanta, and Fashion Valley in San Diego. Simon informed that SHOES FIRST Shopping Guide, a portable print booklet, features the latest range from H&M, Jimmy Choo, Michael Kors, Nine West, Prada, and other brands, which can be purchased at Simon. Mikael Thygesen, Chief Marketing Officer of Simon commented, "The SHOES FIRST™ Shopping Guide provides our shoppers with a beautifully curated showcase of shoes found at our malls. Collaborating with fashion industry leaders such as Marie Claire gives our shoppers an exclusive perspective on trends and reinforces fashion and discovery as key elements of Simon's new brand positioning." The full research reports on Simon are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/SPG/report.pdf

--
The Regions Financial Corporation Research Reports
On October 16, 2014, The Regions Financial Corporation (Regions Financial) announced that its Board of Directors has declared a quarterly cash dividend of 5 cents per common share, payable January 2, 2015, to stockholders of record at the close of business on December 12, 2014. In addition, the Board also declared quarterly cash dividends of c.$15.94 per share each (equivalent to approximately $0.39 per depositary share) on its 6.375% Non-Cumulative Perpetual Preferred Stock, Series A and Non-Cumulative Perpetual Preferred Stock, Series B. According to the Company, the preferred dividends will be payable on December 15, 2014, to stockholders of record at the close of business on December 1, 2014. The full research reports on Regions Financial are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/RF/report.pdf

--
American Capital Agency Corp. Research Reports
On October 16, 2014, American Capital Agency Corp. (American Capital) announced that its Board of Directors has declared a monthly cash dividend of $0.22 per common share for October 2014 payable on November 7, 2014 to common shareholders of record as of October 31, 2014, with an ex-dividend date of October 29, 2014. American Capital informed that the said dividend is the Company's first regular monthly dividend to common shareholders as American Capital previously used to pay common stock dividends on a quarterly basis. The full research reports on American Capital are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/AGNC/report.pdf

--
CareFusion Corporation Research Reports
On October 16, 2014, CareFusion Corporation's (CareFusion) stock declined 0.64% to end the day at $56.33. The stock opened the session at $56.31 and traded in the range of $56.11-$56.72, with a trading volume of 5.25 million shares. The stock has rallied 22.01% after the Company announced on October 5, 2014 that BD would acquire CareFusion for $12.2 billion. The stock closed near its 52-week high of $58.00 and above its 50-day and 200-day moving average of $47.49 and$43.03, respectively. The full research reports on CareFusion are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/CFN/report.pdf

--
Alexion Pharmaceuticals, Inc. Research Reports
On October 15, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced that the Company has submitted a New Drug Application (NDA) for asfotase alfa to Japan's Ministry of Health, Labour and Welfare (MHLW). As per Alexion, asfotase alfa is an investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia (HPP) - a genetic, chronic and progressive ultra-rare metabolic disease. Leonard Bell, M.D., Chairman and CEO of Alexion said, "The NDA submission for asfotase alfa is a critical step toward bringing this highly innovative and much-needed potential treatment to patients in Japan suffering from HPP. If approved, asfotase alfa would be the first therapy for patients with this devastating and life-threatening disorder." The full research reports on Alexion are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/ALXN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review